Bayer traded at 39.25 this Thursday March 12th, decreasing 0.77 or 1.91 percent since the previous trading session. Looking back, over the last four weeks, Bayer lost 14.65 percent. Over the last 12 months, its price rose by 71.40 percent. Looking ahead, we forecast Bayer to be priced at 35.35 by the end of this quarter and at 32.39 in one year, according to Trading Economics global macro models projections and analysts expectations.
Bayer AG is a German-based life science company. The Company's segments are Pharmaceuticals, Consumer Health, Crop Science and Animal Health. The Pharmaceuticals segment focuses on researching, developing and marketing prescription products and specialty therapeutics especially in the areas of cardiology, oncology, gynecology, hematology and ophthalmology, as well as radiopharmacology and others. The company is focusing on their oncology platform o Targeted Alpha Therapies for treating prostate cancer. Th Consumer Health segment develops, produces and markets nonprescription over-the-counter products in the dermatology, dietary supplement, analgesic, gastrointestinal, cold, allergy, sinus and flu, foot care and sun protection categories, among others. The Crop Science segment researches, develops and markets crop protection solutions and seeds, and includes the subsidiary Monsanto. The Animal Health segment is engaged in the development, production and marketing of prescription and non